Effect of the menstrual cycle and oral contraceptives on cyclooxygenase-2 expression in the endometrium

Objective. To compare the expression of cyclooxygenase-2 (COX-2) and proliferation markers (Ki-67) in the endometrium of patients with ovulatory cycles with those in the endometrium of patients using oral contraceptives. Patients and methods. Endometrial biopsies from 104 premenopausal patients with...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gynecological endocrinology 2005-07, Vol.21 (1), p.57-61
Hauptverfasser: Maia, Jr, Hugo, Maltez, Amélia, Studard, Eduardo, Zausner, Bela, Athayde, Célia, Coutinho, Elsimar
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 61
container_issue 1
container_start_page 57
container_title Gynecological endocrinology
container_volume 21
creator Maia, Jr, Hugo
Maltez, Amélia
Studard, Eduardo
Zausner, Bela
Athayde, Célia
Coutinho, Elsimar
description Objective. To compare the expression of cyclooxygenase-2 (COX-2) and proliferation markers (Ki-67) in the endometrium of patients with ovulatory cycles with those in the endometrium of patients using oral contraceptives. Patients and methods. Endometrial biopsies from 104 premenopausal patients with regular ovulatory cycles (n = 90) or using an oral contraceptive (n = 14) were selected for this study. Using immunohistochemical methods, both COX-2 (Novocastra clone 4H12) and Ki-67 (Dako clone MIB-1) expression were determined in the endometrium during the various phases of the menstrual cycle or following the use of oral contraceptives. Results. COX-2 expression in the glandular epithelium was maximal during menstruation, the late proliferative phase and the early luteal phase, and minimal during the late luteal phase. However, in the surface epithelium, COX-2 expression remained strongly positive throughout the luteal phase. Ki-67 positivity increased during the proliferative phase and diminished during the luteal phase in the glands. In contraceptive users, both Ki-67 and COX-2 expression in the endometrium was low. Conclusion.  The increased expression of COX-2 during menstruation and at mid-cycle is eliminated by the continuous use of oral contraceptives. This may be the rationale for their therapeutic action in the treatment of dysmenorrhea and bleeding.
doi_str_mv 10.1080/09513590500099602
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_16048803</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>882945001</sourcerecordid><originalsourceid>FETCH-LOGICAL-c456t-53a7afcd69ecb935c7e823d3c32c63c506e2e41aaaac2eeff9eef2de990b1e193</originalsourceid><addsrcrecordid>eNp9kU9P3DAQxa2qVVloP0AvKOqBW2BsJ04sekGrBSoh9QJny-uMd4MSe7Ed2P32ZP9IbamoD2NZ7_eexjOEfKNwTqGGC5Al5aWEEgCkFMA-kAktKp5DJcRHMtnq-RY4IscxPgJQXlTsMzmiAoq6Bj4hi5m1aFLmbZaWmPXoYgqD7jKzMR1m2jWZD9undylog6vUPmPMvNsB3q83C3Q6Ys4yXK8CxtiOWut2aega32MK7dB_IZ-s7iJ-Pdwn5OF6dj-9ze9-3fycXt3lpihFykuuK21NIySaueSlqbBmvOGGMyO4KUEgw4Lq8RiGaK0cC2tQSphTpJKfkLN97ir4pwFjUn0bDXadduiHqEQNNa0FG8Hvb8BHPwQ39qaorApWQl2NEN1DJvgYA1q1Cm2vw0ZRUNsVqH9WMHpOD8HDvMfmt-Mw8xH4sQdaZ33o9YsPXaOS3nQ-2KCdaaPi_8u__Mu-RN2lpdEB__jBu-5Xbqaodg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>197425087</pqid></control><display><type>article</type><title>Effect of the menstrual cycle and oral contraceptives on cyclooxygenase-2 expression in the endometrium</title><source>Taylor &amp; Francis:Master (3349 titles)</source><source>MEDLINE</source><creator>Maia, Jr, Hugo ; Maltez, Amélia ; Studard, Eduardo ; Zausner, Bela ; Athayde, Célia ; Coutinho, Elsimar</creator><creatorcontrib>Maia, Jr, Hugo ; Maltez, Amélia ; Studard, Eduardo ; Zausner, Bela ; Athayde, Célia ; Coutinho, Elsimar</creatorcontrib><description>Objective. To compare the expression of cyclooxygenase-2 (COX-2) and proliferation markers (Ki-67) in the endometrium of patients with ovulatory cycles with those in the endometrium of patients using oral contraceptives. Patients and methods. Endometrial biopsies from 104 premenopausal patients with regular ovulatory cycles (n = 90) or using an oral contraceptive (n = 14) were selected for this study. Using immunohistochemical methods, both COX-2 (Novocastra clone 4H12) and Ki-67 (Dako clone MIB-1) expression were determined in the endometrium during the various phases of the menstrual cycle or following the use of oral contraceptives. Results. COX-2 expression in the glandular epithelium was maximal during menstruation, the late proliferative phase and the early luteal phase, and minimal during the late luteal phase. However, in the surface epithelium, COX-2 expression remained strongly positive throughout the luteal phase. Ki-67 positivity increased during the proliferative phase and diminished during the luteal phase in the glands. In contraceptive users, both Ki-67 and COX-2 expression in the endometrium was low. Conclusion.  The increased expression of COX-2 during menstruation and at mid-cycle is eliminated by the continuous use of oral contraceptives. This may be the rationale for their therapeutic action in the treatment of dysmenorrhea and bleeding.</description><identifier>ISSN: 0951-3590</identifier><identifier>EISSN: 1473-0766</identifier><identifier>DOI: 10.1080/09513590500099602</identifier><identifier>PMID: 16048803</identifier><identifier>CODEN: GYENER</identifier><language>eng</language><publisher>England: Informa UK Ltd</publisher><subject>Adult ; Contraceptives, Oral - pharmacology ; COX-2 ; Cyclooxygenase 2 - analysis ; Endometrium - enzymology ; Epithelium - enzymology ; Female ; gestodene ; Humans ; Ki-67 ; Ki-67 Antigen - analysis ; Luteal Phase - physiology ; Menstrual Cycle - physiology ; menstruation ; Middle Aged ; Premenopause ; prostaglandins</subject><ispartof>Gynecological endocrinology, 2005-07, Vol.21 (1), p.57-61</ispartof><rights>2005 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2005</rights><rights>Copyright CRC Press Jul 2005</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c456t-53a7afcd69ecb935c7e823d3c32c63c506e2e41aaaac2eeff9eef2de990b1e193</citedby><cites>FETCH-LOGICAL-c456t-53a7afcd69ecb935c7e823d3c32c63c506e2e41aaaac2eeff9eef2de990b1e193</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/09513590500099602$$EPDF$$P50$$Ginformaworld$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/09513590500099602$$EHTML$$P50$$Ginformaworld$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,59620,60409,61194,61375</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16048803$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Maia, Jr, Hugo</creatorcontrib><creatorcontrib>Maltez, Amélia</creatorcontrib><creatorcontrib>Studard, Eduardo</creatorcontrib><creatorcontrib>Zausner, Bela</creatorcontrib><creatorcontrib>Athayde, Célia</creatorcontrib><creatorcontrib>Coutinho, Elsimar</creatorcontrib><title>Effect of the menstrual cycle and oral contraceptives on cyclooxygenase-2 expression in the endometrium</title><title>Gynecological endocrinology</title><addtitle>Gynecol Endocrinol</addtitle><description>Objective. To compare the expression of cyclooxygenase-2 (COX-2) and proliferation markers (Ki-67) in the endometrium of patients with ovulatory cycles with those in the endometrium of patients using oral contraceptives. Patients and methods. Endometrial biopsies from 104 premenopausal patients with regular ovulatory cycles (n = 90) or using an oral contraceptive (n = 14) were selected for this study. Using immunohistochemical methods, both COX-2 (Novocastra clone 4H12) and Ki-67 (Dako clone MIB-1) expression were determined in the endometrium during the various phases of the menstrual cycle or following the use of oral contraceptives. Results. COX-2 expression in the glandular epithelium was maximal during menstruation, the late proliferative phase and the early luteal phase, and minimal during the late luteal phase. However, in the surface epithelium, COX-2 expression remained strongly positive throughout the luteal phase. Ki-67 positivity increased during the proliferative phase and diminished during the luteal phase in the glands. In contraceptive users, both Ki-67 and COX-2 expression in the endometrium was low. Conclusion.  The increased expression of COX-2 during menstruation and at mid-cycle is eliminated by the continuous use of oral contraceptives. This may be the rationale for their therapeutic action in the treatment of dysmenorrhea and bleeding.</description><subject>Adult</subject><subject>Contraceptives, Oral - pharmacology</subject><subject>COX-2</subject><subject>Cyclooxygenase 2 - analysis</subject><subject>Endometrium - enzymology</subject><subject>Epithelium - enzymology</subject><subject>Female</subject><subject>gestodene</subject><subject>Humans</subject><subject>Ki-67</subject><subject>Ki-67 Antigen - analysis</subject><subject>Luteal Phase - physiology</subject><subject>Menstrual Cycle - physiology</subject><subject>menstruation</subject><subject>Middle Aged</subject><subject>Premenopause</subject><subject>prostaglandins</subject><issn>0951-3590</issn><issn>1473-0766</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kU9P3DAQxa2qVVloP0AvKOqBW2BsJ04sekGrBSoh9QJny-uMd4MSe7Ed2P32ZP9IbamoD2NZ7_eexjOEfKNwTqGGC5Al5aWEEgCkFMA-kAktKp5DJcRHMtnq-RY4IscxPgJQXlTsMzmiAoq6Bj4hi5m1aFLmbZaWmPXoYgqD7jKzMR1m2jWZD9undylog6vUPmPMvNsB3q83C3Q6Ys4yXK8CxtiOWut2aega32MK7dB_IZ-s7iJ-Pdwn5OF6dj-9ze9-3fycXt3lpihFykuuK21NIySaueSlqbBmvOGGMyO4KUEgw4Lq8RiGaK0cC2tQSphTpJKfkLN97ir4pwFjUn0bDXadduiHqEQNNa0FG8Hvb8BHPwQ39qaorApWQl2NEN1DJvgYA1q1Cm2vw0ZRUNsVqH9WMHpOD8HDvMfmt-Mw8xH4sQdaZ33o9YsPXaOS3nQ-2KCdaaPi_8u__Mu-RN2lpdEB__jBu-5Xbqaodg</recordid><startdate>20050701</startdate><enddate>20050701</enddate><creator>Maia, Jr, Hugo</creator><creator>Maltez, Amélia</creator><creator>Studard, Eduardo</creator><creator>Zausner, Bela</creator><creator>Athayde, Célia</creator><creator>Coutinho, Elsimar</creator><general>Informa UK Ltd</general><general>Taylor &amp; Francis</general><general>Taylor &amp; Francis Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>20050701</creationdate><title>Effect of the menstrual cycle and oral contraceptives on cyclooxygenase-2 expression in the endometrium</title><author>Maia, Jr, Hugo ; Maltez, Amélia ; Studard, Eduardo ; Zausner, Bela ; Athayde, Célia ; Coutinho, Elsimar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c456t-53a7afcd69ecb935c7e823d3c32c63c506e2e41aaaac2eeff9eef2de990b1e193</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>Contraceptives, Oral - pharmacology</topic><topic>COX-2</topic><topic>Cyclooxygenase 2 - analysis</topic><topic>Endometrium - enzymology</topic><topic>Epithelium - enzymology</topic><topic>Female</topic><topic>gestodene</topic><topic>Humans</topic><topic>Ki-67</topic><topic>Ki-67 Antigen - analysis</topic><topic>Luteal Phase - physiology</topic><topic>Menstrual Cycle - physiology</topic><topic>menstruation</topic><topic>Middle Aged</topic><topic>Premenopause</topic><topic>prostaglandins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Maia, Jr, Hugo</creatorcontrib><creatorcontrib>Maltez, Amélia</creatorcontrib><creatorcontrib>Studard, Eduardo</creatorcontrib><creatorcontrib>Zausner, Bela</creatorcontrib><creatorcontrib>Athayde, Célia</creatorcontrib><creatorcontrib>Coutinho, Elsimar</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>Gynecological endocrinology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Maia, Jr, Hugo</au><au>Maltez, Amélia</au><au>Studard, Eduardo</au><au>Zausner, Bela</au><au>Athayde, Célia</au><au>Coutinho, Elsimar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of the menstrual cycle and oral contraceptives on cyclooxygenase-2 expression in the endometrium</atitle><jtitle>Gynecological endocrinology</jtitle><addtitle>Gynecol Endocrinol</addtitle><date>2005-07-01</date><risdate>2005</risdate><volume>21</volume><issue>1</issue><spage>57</spage><epage>61</epage><pages>57-61</pages><issn>0951-3590</issn><eissn>1473-0766</eissn><coden>GYENER</coden><abstract>Objective. To compare the expression of cyclooxygenase-2 (COX-2) and proliferation markers (Ki-67) in the endometrium of patients with ovulatory cycles with those in the endometrium of patients using oral contraceptives. Patients and methods. Endometrial biopsies from 104 premenopausal patients with regular ovulatory cycles (n = 90) or using an oral contraceptive (n = 14) were selected for this study. Using immunohistochemical methods, both COX-2 (Novocastra clone 4H12) and Ki-67 (Dako clone MIB-1) expression were determined in the endometrium during the various phases of the menstrual cycle or following the use of oral contraceptives. Results. COX-2 expression in the glandular epithelium was maximal during menstruation, the late proliferative phase and the early luteal phase, and minimal during the late luteal phase. However, in the surface epithelium, COX-2 expression remained strongly positive throughout the luteal phase. Ki-67 positivity increased during the proliferative phase and diminished during the luteal phase in the glands. In contraceptive users, both Ki-67 and COX-2 expression in the endometrium was low. Conclusion.  The increased expression of COX-2 during menstruation and at mid-cycle is eliminated by the continuous use of oral contraceptives. This may be the rationale for their therapeutic action in the treatment of dysmenorrhea and bleeding.</abstract><cop>England</cop><pub>Informa UK Ltd</pub><pmid>16048803</pmid><doi>10.1080/09513590500099602</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0951-3590
ispartof Gynecological endocrinology, 2005-07, Vol.21 (1), p.57-61
issn 0951-3590
1473-0766
language eng
recordid cdi_pubmed_primary_16048803
source Taylor & Francis:Master (3349 titles); MEDLINE
subjects Adult
Contraceptives, Oral - pharmacology
COX-2
Cyclooxygenase 2 - analysis
Endometrium - enzymology
Epithelium - enzymology
Female
gestodene
Humans
Ki-67
Ki-67 Antigen - analysis
Luteal Phase - physiology
Menstrual Cycle - physiology
menstruation
Middle Aged
Premenopause
prostaglandins
title Effect of the menstrual cycle and oral contraceptives on cyclooxygenase-2 expression in the endometrium
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T15%3A26%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20the%20menstrual%20cycle%20and%20oral%20contraceptives%20on%20cyclooxygenase-2%20expression%20in%20the%20endometrium&rft.jtitle=Gynecological%20endocrinology&rft.au=Maia,%20Jr,%20Hugo&rft.date=2005-07-01&rft.volume=21&rft.issue=1&rft.spage=57&rft.epage=61&rft.pages=57-61&rft.issn=0951-3590&rft.eissn=1473-0766&rft.coden=GYENER&rft_id=info:doi/10.1080/09513590500099602&rft_dat=%3Cproquest_pubme%3E882945001%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=197425087&rft_id=info:pmid/16048803&rfr_iscdi=true